Aspire’s sublingual aspirin formulation significantly inhibited serum thromboxane B2 (TxB2) within the first two minutes after dosing TxB2 is a biomarker indicating aspirin’s effect on platelet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback